[9] Sulowicz W, Locatelli F, Ryzckelynck J-P, et al. Once-monthly subcutaneous C.E.R.A. maintains stable haemoglobin control in patients with chronic kidney disease on dialysis and convert directly from epoetin one to three times weekly (PROTOS). Clin J Am Soc Nephrol 2007;2:637-646
[10] Fliser D, on behalf of Miracel study group. Once Monthly C.E.R.A. provides stable Hb levels in CKD patients on dialysis following direct switch from short acting ESAs. Abstract SA-PO2669. ASN Annual meeting November 6-9 2008, Philadelphia, PA
[11] MIRCERA(R) Summary of Product Characteristics. F. Hoffmann-La Roche Ltd, 2007
[12] Jarsch M, Brandt M, Haselbeck A. Consumption of C.E.R.A. and epoetin beta in a cellular assay: UT-7 consumption model. Presented at American Society of Hematology (ASH) 48th Meeting, December 9-12, 2006, Orlando, FL
For further information please contact: Julia Pipe at Roche, Tel: +41(0)61-687-4376, Mobile: +41(0)79-263-9715; Diane Lorton at Galliard, Tel: +44(0)207-663-2265, Mobile: +44(0)7717-531-823
